Bicistronic CAR T-cells Against CD70 & Active Integrin β2 Overcome Antigen Heterogeneity and Preserve Safety in Acute Myeloid Leukemia
Authors:
- Amrik S KangAKAmrik S Kang
- Haley JohnsonHJHaley Johnson
- Nicole LeiNLNicole Lei
- Jeremiah WongJWJeremiah Wong
- Nabeel RaziNRNabeel Razi
- Adila IzgutdinaAIAdila Izgutdina
- Corynn KasapCKCorynn Kasap
- Nikhil ChilakapatiNCNikhil Chilakapati
- Jose RiveraJRJose Rivera
- Paul PhojanakongPPPaul Phojanakong
- Juan Antonio Camara SerranoJSJuan Antonio Camara Serrano
- Fernando SalangsangFSFernando Salangsang
Preprint
Abstract
The surface antigen landscape of acute myeloid leukemia (AML) displays significant heterogeneity and overlap with healthy hematopoietic cells. This imparts a substantial hurdle to the development of AML-targeting chimeric antigen receptor (CAR) T-cells that can avoid on- target, off-tumor toxicity. Here, we develop a dual-antigen targeting CAR-T against CD70 and the active conformation of integrin β2 (aITGB2), each previously reported as promising AML targets due to minimal off-tumor expression. We show an OR-gated approach for these antigens significantly increases the proportion of AML blasts that can be targeted, in part using a novel ex vivo co-culture method to restore surface protein homeostasis following a freeze-thaw cycle. We test dual-targeting CAR-T constructs with different combinations of costimulatory domains, identifying constructs with superior anti-tumor cytotoxicity in vitro against AML cell line and patient-derived xenograft models. We further show significantly improved in vivo tumor clearance and survival for a dual-targeting CAR in murine models of AML tumor heterogeneity. Finally, we show that this dual-targeting CAR does not increase off-tumor toxicity, especially against hematopoietic stem and progenitor cells. Together, these findings demonstrate a promising clinically-translatable approach for the treatment of AML without the notable toxicity liabilities associated with other leading CAR-T targets for this disease.Keywords
This publication has 80 references indexed in Scilit:
- Immunotherapeutic targeting of surfaceome heterogeneity in AMLCell Reports, 2024
- Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agentsVirchows Archiv, 2024
- Cooperative CAR targeting to selectively eliminate AML and minimize escapeCancer Cell, 2023
- Anti‐CLL1‐based CAR T‐cells with 4‐1‐BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemiaCancer Medicine, 2023
- Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemiaCancer Cell, 2022
- De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017Cancer, 2021
- Effects of different 2A peptides on transgene expression mediated by tricistronic vectors in transfected CHO cellsMolecular Biology Reports, 2019
- Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AMLCancer Cell, 2017
- The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceCancer Cell, 2016
- Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction TherapyTransplantation and Cellular Therapy, 2015